1210 - california state board of...

S T A T E O F CAL IFORNIA B u d g e t C h a n g e P r o p o s a l - C o v e r S h e e t DF-46 (REV 08/16)

Fiscal Year 2017-18

Business Unit 1111

Department Consumer Affairs

Priority No. 1

Budget Request Name 1111-049-BCP-2017-GB

Program 1210 - CALIFORNIA S T A T E

BOARD OF PHARMACY

Subprogram

Budget Request Description Staff for Outsourcing Facilities and Automated Delivery Systems (Senate Bill 1193)

Budget Request Summary

The California State Board of Pharmacy (Board) is requesting special fund expenditure authorization in the amount of $481,000 in fiscal year 2017-18 and $449,000 in 2018-19 ongoing to fund a 1.0 Supervising Pharmacy Inspector, 2.0 Pharmacy Inspectors and a 0.5 Office Technician to regulate the provisions set forth in Chapter 484, Statutes of 2016 (Senate Bill (SB) 1193). Chapter 484 requires the Board to license both resident and non-resident outsourcing facilities and requires that the outsourcing facility location be inspected prior to issuance or renewal of a license. Additionally, Chapter 484 requires a pharmacy to register an automated drug delivery system with the Board within 30 days of installation and on an annual basis as part of the license renewal.

Requires Legislation Code Section(s) to be Added/Amended/Repealed

• Yes ^ No •

Does this BCP contain information technology (IT) components? • Yes [E] No

Department CIO Date

If yes, departmental Chief Information Officer must sign.

For IT requests, specify the project number, the most recent project approval document (FSR, SPR, S1BA, S2AA, S3SD, S4PRA), and the approval date.

Project No. Project Approval Document: Approval Date:

If proposal affects another department, does other department concur with proposal? • Yes • No Attach comments of affected department, signed and dated by the department director or designee.

Prepared By Date Reviewed By Date

Department Director Date Agency Secretary Date

Additional Review: • Capital Outlay • ITCU • FSCU • OSAE • CALSTARS • Dept. of Technology

BCP Type:

PPBA

• Policy

-By-Tiffany Garcia

• Workload Budget per Government Code 13308.05

Date submitted to the Legislature

ilMn

BCP Fiscal Detail Sheet BCP Title: Pharmacy - Outsourcing Facility Audits and Auto Delivery Systems (SB 1193) BR Name: 1111-049-BCP-2017-GB

B u d g e t R e q u e s t S u m m a r y F Y 1 7 C Y BY BY+1 BY+2 BY+3 BY+4

Personal Services Positions - Permanent 0.0 3.5 3.5 3.5 3.5 3.5

Total Positions 0.0 3.5 3.5 3.5 3.5 3.5

Salaries and Wages Earnings - Permanent 0 281 281 281 281 281

Total Salaries and Wages $0 $281 $281 $281 $281 $281

Total Staff Benefits 0 149 149 149 149 149

Total Personal Services $0 $430 $430 $430 $430 $430

Operating Expenses and Equipment 5301 - General Expense 0 6 6 6 6 6 5302 - Printing 0 2 2 2 2 2

5304 - Communications 0 4 4 4 4 4 5306 - Postage 0 2 2 2 2 2

5320 - Travel: In-State 0 1 1 1 1 1 5322 - Training 0 2 2 2 2 2

5344 - Consolidated Data Centers 0 2 2 2 2 2 5368 - Non-Capital Asset Purchases - Equipment 0 32 0 0 0 0

Total Operating Expenses and Equipment $0 $51 $19 $19 $19 $19

Total Budget Request $0 $481 $449 $449 $449 $449

u n d S u m m a r y Fund Source - State Operations

0767 - Pharmacy Board Contingent Fund, 0 481 449 449 449 449

Total State Operations Expenditures $0 $481 $449 $449 $449 $449

Total All Funds $0 $481 $449 $449 $449 $449

P r o g r a m S u m m a r y Program Funding

1210 - California State Board of Pharmacy Total All Programs $0

481 $481

449 $449

449 $449

449 $449

449 $449

BCP Title: Pharmacy - Outsourcing Facility Audits and Auto Delivery Systems (SB 1193) BR Name: 1111-049-BCP-2017-GB

P e r s o n a l S e r v i c e s Deta i ls

Salary Information Positions Min Mid Max C Y BY BY+1 BY+2 BY+3 BY+4

1 1 3 9 - Office Techn (Typing) 0.0 0.5 0.5 0.5 0.5 0.5 8874 - Supvng Inspector 0.0 1.0 1.0 1.0 1.0 1.0 8876 - Inspector 0.0 2.0 2.0 2.0 2.0 2.0

Total Positions 0.0 3.5 3.5 3.5 3.5 3.5

Salaries and Wages C Y BY BY+1 BY+2 BY+3 BY+4

1139 - Office Techn (Typing) 0 19 19 19 19 19 8874 - Supvng Inspector 0 92 92 92 92 92 8876 - Inspector 0 170 170 170 170 170

Total Salaries and Wages $0 $281 $281 $281 $281 $281

Staff Benefits 5150350 - Health Insurance 0 44 44 44 44 44 5150500 - OASDI 0 21 21 21 21 21 5150600 - Retirement - General 0 75 75 75 75 75 5150800 - Workers'Compensation 0 9 9 9 9 9

Total Staff Benefits $0 $149 $149 $149 $149 $149

Total Personal Services $0 $430 $430 $430 $430 $430

A n a l y s i s of Problem

A. Budget R e q u e s t S u m m a r y

The California State Board of Pharmacy (Board) is requesting special fund expenditure authorization in the amount of $481,000 in f iscal year 2017-18 and $449,000 in 2018-19 ongoing to fund a 1.0 Supervis ing Pharmacy Inspector, 2.0 Pharmacy Inspectors and a 0.5 Office Technic ian to regulate the provisions set forth in Chapter 484, Statutes of 2016 (Senate Bill (SB) 1193). Chapter 484 requires the Board to l icense both resident and non-resident outsourcing facil it ies and requires that the outsourcing facility location be inspected prior to issuance or renewal of a l icense. Addit ionally, Chapter 484 requires a pharmacy to register an automated drug delivery system wi th the Board within 30 days of installation and on an annual basis as part of the l icense renewal.

B. Background/History

The November 2013 enactment of the federal Drug Quality and Security Act responded to a 2012 compounding t ragedy (where a pharmacy compounded a product that was contaminated by fungal material) in a new way: this legislation created a new type of entity authorized to compound medicat ions - the outsourcing facility. These general ly large-scale product ion facilit ies are authorized to compound large quanti t ies of medicat ions for use by other entit ies, whereas a pharmacy generally compounds pursuant to a patient-specif ic prescript ion. Medicat ions prepared by outsourcing facilities must be done under current good manufactur ing practices (or cGMPs) , which are more stringent than compounding requirements for steri le compounding pharmacies, s ince many patients in multiple locations can receive these medicat ions that are not usually l inked to patient-specif ic prescriptions. Chapter 484 expressly author izes that a facility that is registered as an outsourcing facility with the Food and Drug Administrat ion (FDA) shall be concurrent ly l icensed with the Board as an outsourcing facility. Chapter 484 ensures consistent oversight over outsourcing facil it ies doing business within or into Cali fornia and improves consumer protect ion. Such facil it ies play an important role in ensuring access to medicat ions that would otherwise not be available to patients as such are drugs are in short supply.

Because of the inherent risks that come with compounding, under the provisions of Chapter 484, a l icense for an outsourcing facil ity shall not be issued or renewed until the location is inspected by the Board and found to be in compl iance. A l icense for an outsourcing facility shall not be issued or renewed unti l :

• The Board reviews a current copy of the facil it ies policies and procedures for sterile and non-steri le compounding

• The facil ity must provide copies of all federal and state regulatory agency inspection reports, accreditat ion reports and certif ication reports of facil it ies or equipment premises conducted in the prior 12 months

• Prior to inspect ion, the Board must receive a list of all sterile drugs and nonsteri le drug products compounded by the pharmacy as reported to the FDA within the prior 12 months

The outsourc ing facility shall also provide the Board with the fol lowing:

• A copy of any discipl inary act ion or other act ion taken by another state or the FDA within 10 days of the action

• Notice within 24 hours or any recall notice issued by the non-resident outsourcing facility

• A copy of any complaint it received involving an outsourcing facil ity's compounded products f rom or involving any provider, pharmacy or patient in Cali fornia within 72 hours of receipt and

• Notice within 24 hours after learning of adverse effects reported or potentially attributable to a nonresident outsourcing facil i ty's product.

Compound ing pharmacies are especial ly important today to produce needed medicat ions that are in short supply. However, it is equally important that compounding requirements are adhered to by these facil it ies and moni tored for compl iance if being administered to California residents. Chapter 484 adds

l:\Unit\BCP\DF-46_Cover_Sheet_ August 2016.doc


to the strength of the state's oversight of facilit ies that compound non-pat ient specif ic drug products. Oversight of outsourcing facil i t ies is vital to the protection of California consumers.

California law currently permits use of automated drug delivery devices which are mechanical systems control led by a pharmacist or other specif ied health care providers to provide storage, dispensing and distr ibution of dangerous drugs and devices. Use of these delivery devices promotes control and the ability to maintain all t ransact ion information, to accurately track the movement of drugs into and out of the device, for security, accuracy and accountabil i ty whi le providing for quality, potency and purity of the medicat ions. Under some provisions, the pharmacist must authorize the release of medicat ion. The demand for addit ional use of these delivery devices is growing. A pilot study is currently undenway that if proven valuable, wou ld al low patients to pick up medicat ion f rom a delivery device that is not specif ically located in a pharmacy as long as patient consultat ion is first provided.

Pursuant to Chapter 484, a pharmacy that owns or provides dangerous drugs d ispensed through an automated drug delivery system shall register the system by providing the Board in wri t ing with the location of each device within 30 days of installation and on an annual basis as part of the l icense renewal. A pharmacy may only use an automated delivery system if the fol lowing condit ions are met:

• Use of the automated drug delivery system is consistent with legal requirements

• The pharmacy 's policies and procedures related to the automated drug delivery system include appropr iate security measures and monitor ing of the inventory to prevent theft and diversion

• The pharmacy report drug losses f rom the automated drug delivery system as required by law

• The pharmacy l icense is unexpired and not subject to discipl inary condit ion

The registration of these automated drug delivery systems is a beneficial step in Board oversight and enforcement.

Resource History (Dollars in thousands)

Program Budget P Y - 4 P Y - 3 P Y - 2 P Y - 1 PY Authorized Expenditures $14,521 $15,057 $18,155 $20,850 $22,031

Actual Expenditures $12,924 $13,851 $16,719 $19,350 $21,678

Revenues $12,703 $13,933 $14,674 $18,227 $18,843

Authorized Positions 79.2 83.5 79.8 80.8 100.8

Filled Positions 59.0 71.5 74.8 80.8 93.8

Vacancies 20.2 12.0 5.0 0.0 7.0

0 . s ta te Leve l Cons idera t ions

This proposal is consistent wi th the Board's mandate to make public protection its first priority. This mandate is art iculated in Business and Professions Code section 4001.1 which states:

"Protect ion of the public shall be the highest priority for the Cali fornia State Board of Pharmacy in exercising its l icensing, regulatory and disciplinary funct ions. Whenever protection of the public is inconsistent wi th other interests sought to be promoted, the protection of the public shall be paramount."

l:\Unit\BCP\DF-46_Cover_Sheet_August2016.doc


D. Just i f icat ion

On September 22, 2016, the Oovernor s igned SB 1193 which conta ined many important consumer protection provisions. Effective January 1, 2017, any facility registered as an outsourcing facility wi th the FDA needs to be concurrent ly l icensed with the Board as an outsourcing facility if it compounds nonpat ient specif ic medicat ion for distr ibution within or into Cali fornia. The Board is requesting a 1.0 Supervis ing Pharmacy Inspector, 2.0 Pharmacy Inspectors. Outsourc ing inspections are labor intense. A n outsourcing inspection will require at least three full work ing days using two inspectors. The Supervising Pharmacy Inspector is necessary to manage and oversee the inspectors to provide direct ion, monitor ing, leadership and cont inuous training. Supervis ing Inspectors are responsible to review the work product of the Pharmacy Inspector, including but not l imited to, inspection review, investigation review, report review, inspect ion/case assignments and manager ia l duties. Depending on the level of complexi ty of the inspect ion, some inspections will require more than three days with two inspectors. Given the resources required to perform these inspect ions, the Supervising Pharmacy Inspector will assist with the most complex inspections when necessary. The Board's Pharmacy Inspectors work in the field conduct ing pre-l icensure, post l icensure and routine inspections in addit ion to inspect ions as a result of complaints received f rom consumers. These posit ions are necessary to process the provisions of Chapter 484 to l icense and regulate approximately 65 outsourcing facilit ies. The half-t ime Office Technic ian posit ion is being requested to process registrations for automated drug del ivery systems. It is est imated that data entry for approximately 3,000 automated drug delivery sys tems will be processed.

If the Board does not receive the addit ional staff ing to meet the new requirements of Chapter 484, it will be forced to make difficult decis ions to redirect staff f rom other areas of critical need. This will cause invest igat ions of complaints to be postponed and cause undue risk to Cali fornians who have a reasonable expectat ion that their drug supply is safe and properly moni tored by the state. Failure to provide these inspect ions means a fai lure to uphold the Board's public protection mandate.

E . O u t c o m e s and Accountabi l i ty

Chapter 799, Statutes of 2016 (SB 1039) was s igned by the Governor on September 29, 2016. This bill adjusts the Board's fee structure by increasing the statutory caps for a majority of the Board's fees. The at tached fund condit ion shows the projected revenue increase with the Board's new fee structure. The Board will be able to sustain its exist ing operat ions with an appropr iate reserve level with the implementat ion of the Board's new fee structure.

F. A n a l y s i s of All Feas ib le Alternat ives

1. Provide the Board with 3.5 posit ions and $481,000 in 2017-18 and $449,000 in 2018-19 ongoing to fund a 1.0 Supervis ing Pharmacy Inspector, 2.0 Pharmacy Inspectors and a 0.5 Office Technic ian.

Pro: This alternative would al low the Board to fully adhere to the provisions set forth in Chapter 484 whi le maintaining its current level of consumer protections Con: Not approving this alternative will force the Board to redirect staff f rom other mission critical areas. This would be inconsistent with the Board's mandate of protecting the public.

2. Provide the Board with 3.0 posit ions and $439,000 in 2017-18 and $415,000 in 2018-19 ongoing to fund 1.0 Supervis ing Inspector and 2.0 Pharmacy Inspectors.

Pro: This alternative would al low the Board to partially adhere to the provisions set forth in Chapter 484 albeit not to an appropriate level. Con: This alternative would require the Board to redirect resources f rom other mission critical areas to provide support for the Pharmacy Inspectors and process the registrations of the automated del ivery systems.

l:\Unit\BCP\DF-46_Cover_Sheet_August2016.doc


3. Provide the Board with 2.0 posit ions and $285,000 in 2017-18 and $269,000 in 2018-19 ongoing to fund 2.0 Pharmacy inspectors.

Pro: This alternative wou ld al low the Board to partially adhere to the provisions set forth in Chapter 484 albeit not to an appropr iate level.

Con: The Board lacks suff icient resources to appropriately manage the outsourcing facility program. Further, wi th the reduct ion in resources, there could be delays in t ime inspecting facilit ies which could result in shortage of non-pat ient specif ic compounded drugs being available to California patients and cause addit ional stress on a drug market that is already experiencing a shortage. Further, the Board will lack the resources necessary to process the registrations of the automated delivery sys tems making managing of such information extremely chal lenging. This would require the Board to redirect resources f rom other mission critical areas, which is inconsistent with the Board's mandate of protect ing the public.

4 . Status Quo - This should not be an option as it will result in the Board's inability to implement the consumer protect ion provisions contained in Chapter 484. The Board will lack the resources needed to regulate outsourc ing facil it ies which will have a signif icant and detr imental effect on Cali fornia consumers. Further, the Board will be unable to readily identify the use of automated delivery sys tems and therefore unable to ensure they are being used consistent with the provisions of the law.

Pro: This alternative wou ld not require addit ional funding. Con: If the Board does not receive the addit ional staffing to meet the new requirements of Chapter 484, it will be forced to make difficult decis ions to redirect staff f rom other areas of critical need. This will cause invest igat ions of complaints to be postponed and cause undue risk to Californians who have a reasonable expectat ion that their drug supply is safe and properly monitored by the state. Failure to provide these inspections means a fai lure to uphold the Board's public protection mandate.

G . Implementation Plan

The Board will initiate the hiring process using the posit ion authority and funding received to recruit for the approved posit ion.

H. Supplementa l Information

Please see the at tached work load, fund condit ion and organizat ion chart.

I. Recommendat ion

The Board recommends alternative one as it is the only option that will al low the Board to meet the requirements of Chapter 484 whi le ensur ing the safety of Cali fornians and preventing any additional shortage of an already strained drug supply.

l:\Unit\BCP\DF-46_Cover_Sheet_August 2016.doc

SB 1193 Outsourcing Facilities and Automated Drug Delivery Systems Workload Chart

Off ice Technic ian (0.5) W o r k l o a d FY 2017-18 # TIMES HOURS TO TOTAL

TASK REFORM TIME/HOURS

PERFORMED TASK ANNUALLY

Data ent ry on locat ions o f a u t o m a t e d d rug del ivery 3,000 0.25 750

systems

Process Mai l 500 0.09 45

A d m i n Funct ions (e-mai l , meet ings, etc.) 52 2 104

To ta l T i m e 899 hours

Posi t ions Needed O.S

Superv is ing Inspector (1.0) W o r k l o a d FY 2017-18 # TIMES TASK PERFORMED

HOURSTO REFORM TASK

TOTAL TIME/HOURS ANNUALLY*

Review Policies and Procedures/Product Lists 5 8 40

Outsourc ing Inspec t ions** 9 40 360

Assign Inspections 63 1 63

Review Recal ls/ADRs fo r Possible Invest igat ion 50 2 100

FDA 483 - Reconci l iat ion ( including FDA Liaison) 12 4 48

Assign Invest igat ions (Plan and Assessments, etc.) 15 1 15

Review Invest igat ion Reports 15 4 60

CGMP Train ing 1 80 80

Supervisor Duties (guidance, t ra in ing , e-mails,

pe r fo rmance appraisals, admin funct ions)

52 8 416

Week ly Supervisor Conference Calls 48 1.5 72

M o n t h l y Conference Meet ings w i t h Staff 12 3 36

A t t e n d Board /Commi t tee Meet ings 6 8 48

Program M a n a g e m e n t (Develop Inspect ion Forms,

Self-Assessment Form, Regulat ions, Ma in tenance, etc.)

12 32 384

Bi-Annual Staff M e e t i n g s / Manager Meet ings 6 16 96

To ta l T i m e 1,818 hours

Posi t ions Needed 1.0

Inspectors (2.0) W o r k l o a d FY 2017-18 # TIMES TASK PERFORMED

HOURSTO REFORM TASK

TOTAL TIME/HOURS ANNUALLY*

Review Policies and Procedures/ Product Lists 58 8 464

Outsourc ing Inspect ions* 58 40 2,320

Invest igat ions 15 16 240

Report W r i t i n g 15 6 90

CGMP Train ing 2 80 160

Bi- Annual Staff Meet ings 4 24 96

9/28/16 Page 1 of 2

SB 1193 Outsourcing Facilities and Automated Drug Delivery Systems Workload Chart

A d m i n Funct ions (travel claims, e-mai l , etc. 104 1 104

M o n t h l y Conference calls 24 3 72 Total Time 3,546

(1,773 per Inspector)

Positions Needed 2.0

*The Inspectors will travel statewide and out of state to perform annual state mandated inspections of outsourcing facilities. Inspections for licensure and renewal will ensure compliance with operational requirements, pharmacy laws and regulations. The inspection process includes an inspection of the outsourcing facility and review of policies and procedures, review of federal and state regulatory agency inspection reports, accreditation reports, certification reports of facilities or equipment premises conducted in prior 12 months, review of all sterile and nonsterile drug products compounded by the pharmacy as reported to the FDA in the prior 12 months and review of any disciplinary action taken by another state or the FDA. Inspectors will also review of the quantity and type of preparations compounded, collect evidence, write reports, interview staff, educate staff and issue orders of correction as appropriate. The inspectors investigate and/or mediate complaints alleging violations of the pharmacy practice act, specifically laws related to outsourcing facilities.

* * This includes inspections conducted alone by the Supervisor as well as semi-annual inspections with staff for training purposes, evaluating staff, etc.

9/28/16 Page 2 of 2

D e p a r t m e n t o f C o n s u m e r A f f a i r s

Board of Pharmacy S e p t e m b e r 2 0 1 6

Executive Officer Virginia Herold

632-110-8916-001

Julia Ansel Chief of Enforcement

C E A (Range A) 632-110-7500-002

Anne Sodergren Assistant Executive Officer

C E A (Range B ) 632-110-7500-001

Vai'iiiit Chief of Enforcement

C E A (Range A) 632-110-7500-003

CURRENT FY 2016-17

Authorized positions: 100.8 BL 12-03 (999 Bianket): 3.7

Page 1

V a c a n t Limited TeriT! B l a n k e t 907 Blanket 999

Frac t i ona l

Christin Super

Insp 632-110-

e Acosta vising ector 8874-011

Compounding

Pharmacy Inspector

(7)

Suzy Patell 632-110-8876-012

Joshua Lee 632-110-8876-016

Margaret Panella-Spangler

632-110-8876-028

Anna Kalantar 632-110-8876-606

Craig Jeffers 632-110-8876-607

l.liula Paiiofslcy ( l entative)

632-110-8876-608

Denise Dukatz 632-110-8876-609

William Young Supervising

Inspector 632-110-8874-005

Compliance Investigation

Pharmacy Inspector

(4)

Anna Yamada 632-110-8876-003

Kavita Nankani (lentative)

632-110-8876-013

Sejal Desai 632-110-8876-025

Ben Rustia 632-110-8876-027

De'Bor Super

Insp 632-110-

a White vising Ector 8874-010


Pharmacy Inspector

(4)

.lulla Krunier (Tentative)

632-110-8876-019

Michael Boluro-Ajayi

632-110-8876-021

Phillip Wright 632-110-8876-023

Joseph Wong 632-110-8876-032

Jeff Smith (RA) 632-110-8876-907

Anne Hunt Supervising

Inspector 632-110-8874-008


Pharmacy Inspector

(5)

Valerie Sakamura 632-110-8876-004

Scott Huhii (Tentative)

632-110-8876-031

Sara Mullen 632-110-8876-035

V a t a i i i ( I l ix lnc l t ) 632-110-8876-043

Lin Hokana 632-1 10-88"6-6llS

Joan Coyne Supervising

Inspector 632-110-8874-009

Probation Monitoring/ Drug Diversion for

Self-Use

Pharmacy Inspector

(5)

Diann Potter 632-110-8876-007

Katherine Sill 632-110-8876-036

Hilda Nip 632-110-8876-037

Simin Samari 632-110-8876-041

Trang Song 632-110-8876-002

Janice Dang Supervising

Inspector 632-110-8874-003

Drug Diversion & Fraud

Pharmacy Inspector

(5)

Brandon Mutrux 632-110-8876-005

Moneet Kaur 632-110-8876-006

Sarah Kim 632-110-8876-022

Christopher Woo 632-110-8876-014

Karla Retherford-Parreira 632-110-8876-033

Michael Ignacio Supervising

Inspector 632-110-8874-006

Drug Diversion & Fraud

Pharmacy Inspector

(4)

Jennifer Hall 632-110-8876-010

Patricia Peterson 632-110-8876-011

Manisha Shafir 632-110-8876-026

Elhain Dclniic ( i eiitativc)

632-110-8876-034

Antony Ngondara (LT) Supervising

Inspector 632-110-8874-600

Prescription Drug Abuse

Pharmacy Inspector

(5)

Steven Kyle 632-110-8876-600

Irina Top 632-110-8876-601

Connie Tang 632-110-8876-602

Noelle Randall 632-110-8876-603

Michael Capili 632-110-8876-604

Executive Officer or Designee Date

September 19, 2016

Classification & Pay Analyst Date

D e p a r t m e n t o f C o n s u m e r A f f a i r s

Board of Pharmacy S e p t e m b e r 2 0 1 6

Executive Officer Virginia 1 lerold

632-110-8916-001

Clii istinc Aocsla Siipci \ising

Inspector 10-8X74-01 I

t i i i i ip tn i i id i i iu

Julia Ansel Cliicr of Eiiforcemciir

f U A (Raiisc A) 632-110-7300-002

Anne .Sodergren .As.slstaiil Executive Officer

f EA (Range 1$) 632-110-7.300-001

Wiliiiini "t'oiiiig Siipcivlsiiig

Inspector 632-110-8874-005

Dc'lJora White .Supervising

In.spcetor 632-110-8874-010

C'diiiplianee Investigation

Anne 1 lunl Supervising

Inspector 632-110-8874-008

Compliance Invcsliuaiion


I'hiiiniacj I'harniiicy Pharniacy j Pharmacy Inspector Inspector Inspector Inspeclor

(7) (•») (•«) j (5)

Su/.y Palcll Anna Yamada i .(ulia Kriiincr I Valeric Sakamura (A2-i iO-XX76-012 632-110-8876-003 i ( rcntallvc)

632-110-8876-019 ; 632-110-8876-004

loshiia l.cc Kavita Natikaiii Scott llitlin o.m-i iu-X87h-0l6 (1 ciitalivc)

632-110-8.876-013 •

Michael Holiiro-Ajayi

i (Teiilalivc) i 632-110-8876-031

Margaret 6.32-110-8876-021 1

I'aiieila-Spanglcr Sejal Desui Sara Mullen 63:-nO-,XX76-02X 63.2-110-8,876-025 ' Phillip Wright

632-1 10-8876-023 632-1 10-8876-035

Anna Kalaiilar lien RiLslia Vacant (lloditctt) 632-1 10-8876-606 632-110-8876-027 [ Joseph Wong ; 632-110-8876-043

632-110-8876-032 Craig Jcllcrs

632-110-8876-032 Lin Hokana

632-1 iO-,S>S7(>-6()7 JclTSmUlKRA) 632-110-8876-605 632-1 10-8876-907

Eliida I'anofskv 632-1 10-8876-907

(I ciitativc) 6 .M - I !t)-,S876-60S

Detiise Diikal/ |M2-i 1(1-8876-609

Proposed Supervising

Inspector 632-110-8874-XXX

Oulsoiircing

I'liariiiacy Inspector

(2)

Proposed i>iC-l l ( ) -SS7( . - . \ \

Proposed ( ) t M IO-8.S7»-X.V\

Joan Coyne Supervising

liispcctor 632-110-8874-009

Probation Monitoring,' Drug Diversion lor

Self-Use

Pharmacy Inspector

(5)

Diann Poller 632-110-8876-007

Kalhcrinc Sill 632-1 10-8876-036

Hilda Nip 632-110-8876-037

Simin Samari 632-1 10-8876-041

Ti ang Song 632-110-8876-002

Vacant Chlefof Enforcement

C E A (Range A) 632-110-7500-003

PROPOSED FY 2017-18

Authorized positions: 104.3 BL 12-03 (999 Bianket): 3.7

Page 1

Vacant L im i t ed T e r m B l a n k e t 9 0 7 Blanket 999

F r a c t i o n a l

Janice Dang Siipcrvlslng

Inspector 632-110-8874-003

Drug Diversion & I raud

Pharinacy Inspector

Brandon Mulrii.x 632-1 10-8876-005

Moneet Kanr 632-110-8876-006

Sarah Kim 632-110-8876-022

Chi i.stopher Won 632-110-8876-014

Karla Rcthcrrord-Parrcira 632-110-8876-033

!

Michael Ignacio Supervising

Inspector 632-110-8874-006

Drug Diversion & l-raiid

I'liariitaey litspcrtof

(4)

.lennilcr Hall 632-110-8876-010

Patricia Pclersim 632-110-8876-011

Manisha Slialh 632-110-8876-026

Eiham Dciiiiie ( l eotalltc)

632-1 10-8876-034

Antony Ngoiulaia (1.1) Supervising

Inspector 632-i 10-8874-600

r'iv.scri|)t/on Drug Abuse

Phaitiiiicy Inspector

.Steven Kyle 632-110-8X76-600

Irina lop 632-110-8876-601

Connie J ang ; 632-110-8876-602 |

Xocllc Randall I 632-110-SS76-6O3

Michael Capili | 632-110-8876-604 |

E x e c u t i v e O f f i ce r or D e s i g n e e D a t e

S e p t e m b e r 19, 2 0 1 6

C l a s s i f i c a t i o n & P a y A n a l y s t D a t e

0767 - State Board of Pharmacy Analysis of Fund Condition

(Dollars in Thousands)

2017-18 Governor's Budget

B E G I N N I N G B A L A N C E

Prior Year Adjustment Adjusted Beginning Balance

R E V E N U E S A N D T R A N S F E R S

Revenues: 125600 Other regulatory fees 125700 Other regulatory licenses and permits 125800 Renewal fees 125900 Delinquent fees 131700 Misc. revenue from local agencies 141200 Sales of documents 142500 Miscellaneous services to the public 150300 Income from surplus money investments 160100 Settlements and Judgements - AntI Trust Actions 150500 Interest Income From Interfund Loans 160400 Sale of fixed assets 161000 Escheat of unclaimed checks and warrants 161400 Miscellaneous revenues Totals, Revenues

Transfers to Other Funds:

Totals, Revenues and Transfers

Totals, Resources

E X P E N D I T U R E S

Disbursements: 1110 Program Expenditures (State Operations) 1111 Program Expenditures (State Operations) Outsourcing Facility BCP (SB 1193) 8880 RISC (State Operations) 9900 Statewide Pro Rata

Total Disbursements

F U N D B A L A N C E

Reserve for economic uncertainties

M o n t h s in R e s e r v e

01.03.17

Budget Governor's Act Budget

ACTUAL CY BY BY+1 2015-16 2018-17 2017-18 2018-19

$ 11,742 $ 10,518 $ 7,725 $ 10,093 $ 26 $ - $ - $ -$ 11,768 $ 10,518 $ 7,725 $ 10,093

$ 2,288 $ 1,841 $ 1,666 $ 1,666 $ 3,529 $ 3,547 $ 4,819 $ 4,819 $ 12,748 $ 12,283 $ 18,726 $ 18,726 $ 193 $ 191 $ 205 $ 205 $ 4 $ - $ - $ -$ - $ - $ - $ -$ - $ - $ - $ -$ 49 $ - $ - $ -$ - $ - $ - $ -$ - $ - $ - $ -$ 1 $ - $ - $ -$ 13 $ - $ - $ -$ 10 $ - $ - $ -$ 18,835 $ 17,862 $ 25,416 $ 25,416

$ 18,835 $ 17,862 $ 25,416 $ 25,416

$ 30,603 $ 28,380 $ 33,141 $ 35,509

$ 20,050 $ $ $ $ - $ 19,464 $ 21,193 $ 21,658 $ - $ - $ 481 $ 449 $ 35 $ 26 $ 27 $ -$ - $ 1,165 $ 1,347 $ 1,347 $ 20,085 $ 20,655 $ 23,048 $ 23,454

$ 10,518 $ 7,725 $ 10,093 $ 12,055

6.1 4.0 5.2 6.1

1210 - california state board of...

Documents